Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
Informacje o tej pozycji
NACRES:
NA.32
UNSPSC Code:
51111800
Form:
lyophilized
Assay:
≥98% (HPLC), ≥98% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
28.6 kDa
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócbiological source
human
recombinant
expressed in E. coli
assay
≥98% (HPLC), ≥98% (SDS-PAGE)
form
lyophilized
potency
≤0.3 μg/mL
mol wt
28.6 kDa
packaging
pkg of 25 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
color
white to off-white
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... IGFBP5(3488)
General description
IGFBP5 (insulin-like growth factor-binding protein 5) belongs to the IGFBP family of proteins. IGFBPs are mainly required to regulate IGFs (insulin like growth factors) activities. The gene IGFBP5 is mapped to human chromosome 2q35.
Recombinant human IGF-BP5 is a 28.6kDa protein consisting of 253 amino acid residues.
Recombinant human IGF-BP5 is a 28.6kDa protein consisting of 253 amino acid residues.
Biochem/physiol Actions
IGFBP5 (insulin-like growth factor-binding protein 5) works via IGF (insulin like growth factor)-dependent and -independent mechanisms. It can function as a tumor suppressor as well as an oncogene. Changes in the activity of this gene are often observed in human cancers and metastatic tissues. During cancer development, IGFBP5 is involved in cell growth, migration and invasion. IGFBP5 is associated with breast cancer, osteosarcoma, head and neck squamous cell carcinoma, neuroblastoma, prostate cancer and malignant melanoma. It is upregulated in systemic sclerosis and idiopathic pulmonary fibrosis. In primary fibroblasts, IGFBP5 exhibits pro-fibrotic effects. It is strongly expressed in bones and is involved in osteogenic differentiation. Under in vitro conditions, IGFBP5 and its microRNA (microRNA-143-3p) are involved in muscle regeneration.
Physical form
Lyophilized from 10 mM Sodium Citrate, pH 3.0.
Preparation Note
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.
Other Notes
MLGSFVHCEP CDEKALSMCP PSPLGCELVK EPGCGCCMTC ALAEGQSCGV YTERCAQGLR CLPRQDEEKP LHALLHGRGV CLNEKSYREQ VKIERDSREH EEPTTSEMAE ETYSPKIFRP KHTRISELKA EAVKKDRRKK LTQSKFVGGA ENTAHPRIIS APEMRQESEQ GPCRRHMEAS LQELKASPRM VPRAVYLPNC DRKGFYKRKQ CKPSRGRKRG ICWCVDKYGM KLPGMEYVDG DFQCHTFDSS NVS
Ta strona może zawierać tekst przetłumaczony maszynowo.
Klasa składowania
11 - Combustible Solids
Co się dzieje?
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.